AE Risk Examined for Abiraterone, Enzalutamide in Prostate Cancer

Risk for metabolic or cardiovascular adverse events increased for men receiving abiraterone or enzalutamide for advanced disease
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Oncology, Pharmacy, Urology, Journal, Source Type: news